| Literature DB >> 24430001 |
Whitney Wharton1, Carey E Gleason2, N Maritza Dowling3, Cynthia M Carlsson2, Eliot A Brinton4, M Nanette Santoro5, Genevieve Neal-Perry6, Hugh Taylor7, Frederick Naftolin8, Rogerio A Lobo9, George Merriam10, Joann E Manson11, Marcelle I Cedars12, Virginia M Miller13, Dennis M Black14, Matthew Budoff15, Howard N Hodis16, S Mitchell Harman17, Sanjay Asthana2.
Abstract
Midlife vascular risk factors influence later cognitive decline and Alzheimer's disease (AD). The decrease in serum estradiol levels during menopause has been associated with cognitive impairment and increased vascular risk, such as high blood pressure (BP), which independently contributes to cognitive dysfunction and AD. We describe the extent to which vascular risk factors relate to cognition in healthy, middle-aged, recently postmenopausal women enrolled in the Kronos Early Estrogen Prevention Cognitive and Affective Study (KEEPS-Cog) at baseline. KEEPS-Cog is a double-blind, randomized, placebo-controlled, parallel group, clinical trial, investigating the efficacy of low-dose, transdermal 17β-estradiol and oral conjugated equine estrogen on cognition. All results are cross-sectional and represent baseline data only. Analyses confirm that the KEEPS-Cog cohort (n = 571) was middle aged (mean 52.7 years, range 42-59 years), healthy, and free of cognitive dysfunction. Higher systolic BP was weakly related to poorer performance in auditory working memory and attention (p = 0.004; adjusted for multiple comparisons p = 0.10). This relationship was not associated with endogenous hormone levels, and systolic BP was not related to any other cognitive domain. BP levels may be more sensitive than other vascular risk factors in detecting subtle differences in cognitive task performance in healthy, recently menopausal women. Lower BP early in menopause may affect cognitive domains known to be associated with AD.Entities:
Keywords: Attention; blood pressure; clinical trial; cognition; estradiol; estrogen; hormone therapy; memory; vascular risk
Mesh:
Substances:
Year: 2014 PMID: 24430001 PMCID: PMC4367860 DOI: 10.3233/JAD-130245
Source DB: PubMed Journal: J Alzheimers Dis ISSN: 1387-2877 Impact factor: 4.472